Danqi Chen
State Key Laboratory Of Drug Research
Shanghai, China
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Development of 2,8-diazaspiro[4.5]decan-3-ones as novel sigma-1 receptor antagonists and evaluation of antihyperalgesic effects.
Journal: Bioorganic chemistry
Published: January 21, 2026
Design of Selective BRD4 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease.
Journal: Journal of medicinal chemistry
Published: February 13, 2025
Structure-Based Rational Design and Evaluation of BET-Aurora Kinase Dual-Inhibitors for Treatment of Cancers.
Journal: Journal of medicinal chemistry
Published: January 23, 2025
Design and development of a series of 4-(piperazin-1-yl)pyrimidines as irreversible menin inhibitors.
Journal: European journal of medicinal chemistry
Published: August 19, 2024
2,6-diazaspiro[3.4]octan-7-one derivatives as potent sigma-1 receptor antagonists that enhanced the antinociceptive effect of morphine and rescued morphine tolerance.
Journal: European journal of medicinal chemistry
Published: December 13, 2022
Design, synthesis and biological evaluation of 4-aminoquinoline derivatives as receptor-interacting protein kinase 2 (RIPK2) inhibitors.
Journal: Journal of enzyme inhibition and medicinal chemistry
Published: November 21, 2022
Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Journal: European journal of medicinal chemistry
Published: October 25, 2022
Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities.
Journal: European journal of medicinal chemistry
Published: April 13, 2022
Structure-Based Discovery of Potent CARM1 Inhibitors for Solid Tumor and Cancer Immunology Therapy.
Journal: Journal of medicinal chemistry
Published: November 16, 2021
Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1H-pyrazol-4-yl) amino) quinazolin-6-yl)-N-(3-(trifluoromethyl) phenyl) benzamides as potent discoidin domain receptor inhibitors for the treatment of idiopathic pulmonary fibrosis.
Journal: Acta pharmaceutica Sinica. B
Published: July 28, 2021
Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis.
Journal: Acta pharmacologica Sinica
Published: April 12, 2021
Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: October 23, 2020
Last Updated: 09/26/2026